FDA Submission Update for ANDA220724 by Zydus Pharmaceuticals
Zydus Pharmaceuticals has submitted ANDA220724 with a standard review priority.
Asset / Drug
Drug and asset intelligence for ANDA220724 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.